Cargando…

Effects of door‐to‐tolvaptan time on short‐term clinical outcome in patients with acute heart failure

AIMS: We investigated the effects of door‐to‐tolvaptan (D2T) time on short‐term urine volume and in‐hospital clinical outcomes in patients with acute heart failure (AHF). METHODS AND RESULTS: Patients with AHF, treated with tolvaptan at two hospitals, were enrolled in this retrospective observationa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nomura, Ryohei, Morishita, Tetsuji, Sato, Yusuke, Aoyama, Daisetu, Shimizu, Tomohiro, Uzui, Hiroyasu, Nakano, Akira, Tada, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682855/ https://www.ncbi.nlm.nih.gov/pubmed/37752742 http://dx.doi.org/10.1002/ehf2.14530

Ejemplares similares

Sequential organ failure assessment score on admission predicts long‐term mortality in acute heart failure patients
por: Aoyama, Daisetsu, et al.
Publicado: (2020)

Association between Changes in the Systolic Blood Pressure from Evening to the Next Morning and Night Glucose Variability in Heart Disease Patients
por: Shimizu, Tomohiro, et al.
Publicado: (2021)

Association between matrix metalloproteinase‐9 and worsening heart failure events in patients with chronic heart failure
por: Morishita, Tetsuji, et al.
Publicado: (2017)

Effects of PCSK9 Inhibitor on Favorable Limb Outcomes in Patients with Chronic Limb-Threatening Ischemia
por: Sato, Yusuke, et al.
Publicado: (2021)

Effects of Sitagliptin on the Coronary Flow Reserve, Circulating Endothelial Progenitor Cells and Stromal Cell-derived Factor-1alpha
por: Morishita, Tetsuji, et al.
Publicado: (2019)

Pseudo superior vena cava entrance block during sinus rhythm uncovered by continuous atrial pacing
por: Sekihara, Takayuki, et al.
Publicado: (2022)

Focal post‐Maze atrial tachycardia mimicking macroreentrant tachycardia around the Maze lesion diagnosed using ultra‐high‐resolution mapping
por: Sekihara, Takayuki, et al.
Publicado: (2022)

Atrial fibrillation activation patterns predict freedom from arrhythmias after catheter ablation: utility of ExTRa mapping™
por: Aoyama, Daisetsu, et al.
Publicado: (2023)

Significance of day-to-day glucose variability in patients after acute coronary syndrome
por: Miyoshi, Machiko, et al.
Publicado: (2021)

Tolvaptan, hyponatremia, and heart failure
por: Zmily, Hammam D, et al.
Publicado: (2011)

Predictive Utility of the Changes in Matrix Metalloproteinase‐2 in the Early Phase for Left Ventricular Reverse Remodeling After an Acute Myocardial Infarction
por: Morishita, Tetsuji, et al.
Publicado: (2015)

Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure
por: Katsumata, Mari, et al.
Publicado: (2017)

Acarbose treatments improve arterial stiffness in patients with type 2 diabetes mellitus
por: Uzui, Hiroyasu, et al.
Publicado: (2011)

Preprocedural Troponin T Levels Predict the Improvement in the Left Ventricular Ejection Fraction After Catheter Ablation of Atrial Fibrillation/Flutter
por: Aoyama, Daisetsu, et al.
Publicado: (2020)

Hemodynamic and Hormonal Effects of Tolvaptan for Heart Failure
por: Kiuchi, Shunsuke, et al.
Publicado: (2018)

Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria
por: Takagi, Koji, et al.
Publicado: (2017)

Role of Liver Transplantation in Tolvaptan-Associated Acute Liver Failure
por: Endo, Mayumi, et al.
Publicado: (2019)

The characteristics and outcomes in patients with acute heart failure who used tolvaptan: from KCHF registry
por: Nishikawa, Ryusuke, et al.
Publicado: (2023)

Impact of renal function on mid-term outcomes in heart failure patients treated with tolvaptan
por: Fujioka, Kensuke, et al.
Publicado: (2019)

Total body fluid is the factor that affects the pharmacokinetics of tolvaptan, and its efficacy, in acute worsening heart failure patients
por: Kato, Takahiro, et al.
Publicado: (2023)

Tolvaptan: A Novel Diuretic in Heart Failure Management
por: Zulkifli Amin, Hilman, et al.
Publicado: (2016)

Long-Term Tolvaptan Treatment in Refractory Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2019)

Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial
por: Komiya, Shiro, et al.
Publicado: (2022)

Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure
por: Ikeda, Shuntaro, et al.
Publicado: (2017)

Temporal trends in tolvaptan use after revision of national heart failure guidelines in Japan
por: Yamazaki, Yusuke, et al.
Publicado: (2021)

Echocardiographic characteristics of patients with acute heart failure requiring tolvaptan: a retrospective study
por: Nakada, Yasuki, et al.
Publicado: (2015)

Renoprotection by long‐term low‐dose tolvaptan in patients with heart failure and hyponatremia
por: Oka, Tatsufumi, et al.
Publicado: (2021)

Long-term effects of tolvaptan in patients requiring recurrent hospitalization for heart failure
por: Ogawa, Hayato, et al.
Publicado: (2015)

Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients
por: Nodari, Savina, et al.
Publicado: (2010)

Tolvaptan for water retention in heart failure: a systematic review
por: Pan, Yujing, et al.
Publicado: (2023)

The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure
por: Otsuka, Tomoyuki, et al.
Publicado: (2013)

A new paradigm for the treatment of volume overload in heart failure-combined effect of tolvaptan with furosemide
por: Okamoto, Hiroshi
Publicado: (2013)

Prognostic Impact of the Early Use of Tolvaptan in Elderly Patients with Acute Decompensated Heart Failure
por: Okada, Tomoaki, et al.
Publicado: (2023)

Efficacy and safety of intravenous OPC‐61815 compared with oral tolvaptan in patients with congestive heart failure
por: Sato, Naoki, et al.
Publicado: (2022)

Tolvaptan
por: Rangarajan, Bharath, et al.
Publicado: (2014)

Tolvaptan: the evidence for its therapeutic value in acute heart failure syndrome
por: Aghel, Arash, et al.
Publicado: (2008)

Renoprotective effect of tolvaptan in patients with new‐onset acute heart failure
por: Kin, Hiromi, et al.
Publicado: (2020)

Predictors of in-hospital mortality in elderly patients with heart failure treated with tolvaptan
por: Kobayashi, Masakazu, et al.
Publicado: (2023)

Initiation and long-term use of tolvaptan for patients with worsening heart failure through hospital and clinic cooperation
por: Uemura, Yusuke, et al.
Publicado: (2021)

Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure
por: Jujo, Kentaro, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vfp5j78uv4tuct0rqnpc07bn59